Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.1%

1 terminated/withdrawn out of 14 trials

Success Rate

88.9%

+2.3% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

3 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

4(33.3%)

N/A

4(33.3%)

Phase 3

3(25.0%)

Phase 1

1(8.3%)

12Total

Phase 2(4)

N/A(4)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05918861Phase 3Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Role: collaborator

NCT06101784Phase 1Completed

Single and Multiple Ascending Oral Doses of Avenanthramide

Role: collaborator

NCT04970888Not ApplicableRecruiting

Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure

Role: collaborator

NCT02387229Phase 3Terminated

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Role: collaborator

NCT04962061Not ApplicableRecruiting

A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors.

Role: collaborator

NCT04467905Phase 2Completed

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Role: collaborator

NCT03857256Phase 2Completed

Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

Role: collaborator

NCT05223426Not ApplicableUnknown

Effects of Individualized Cognitive Training on Cognition in Heart Failure

Role: collaborator

NCT05212831Not ApplicableCompleted

Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.

Role: collaborator

NCT04676867Phase 2Completed

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Role: collaborator

NCT02525939Phase 3Completed

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Role: collaborator

NCT03239366Phase 2Unknown

A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population

Role: collaborator

NCT02831907Completed

Portal Flow Pulsatility as a Risk Factor for Acute Kidney Injury After Cardiac Surgery

Role: collaborator

NCT02658006Completed

Evaluation of Monitoring TECHNOlogies in the PERI-OPerative Care of Cardiac Surgical Patients

Role: collaborator

All 14 trials loaded